Mol Psychiatry 28:284297 Frost G, Sleeth ML, Sahuri-Arisoylu M, Lizarbe B, Cerdan S, Brody L, Anastasovska J, Ghourab S, Hankir M, Zhang S, Carling D, Swann JR, Gibson G, Viardot A, Morrison D, Louise Thomas E, Bell JD (2014) The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism
Wegovy (semaglutide) is a GLP-1 receptor agonist licensed for weight management in adults with obesity or overweight with comorbidities
But the differences in data and the challenges of integrating it often lead to biased predictions, and thats a big limitation for this technology
It belongs to a class of medications called GLP1/GIP dual agonists, or glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonists
These figures reflect results from clinical trials of the active ingredients, not from Novi's program specifically
Patients with persistent thirst despite GLP-1 therapy may need evaluation for inadequate glycemic control
